Impact of Coronary Stent Design in Proximal Balloon Edge Dilation Technique for Bifurcation Percutaneous Coronary Intervention

Percutaneous Coronary Intervention for Bifurcation Coronary Disease

Correspondence to: Dr Yves Louvard, Institut Cardiovasculaire Paris Sud, Institut Hospitalier Jacques Cartier, 6 avenue du Noyer Lambert, 91300 Massy, France; [email protected] _________________________ E ver since coronary angioplasty was first undertaken, treatment of coronary bifurcation lesions has posed technical problems. w2 Specific difficulties involving access to the side branch an...

Percutaneous coronary intervention of bifurcation coronary disease.

Bifurcation coronary artery disease is a frequent problem faced by interventional cardiologists and it affects approximately 15-20% of patients undergoing percutaneous coronary intervention (PCI). The application of drug-eluting stents (DES) technology to prevent restenosis after PCI represents one of the success stories in cardiology, but DES have not resolved the bifurcation PCI challenge. Bi...

Use of RTM stent in the percutaneous coronary intervention of coronary bifurcation lesions

Percutaneous intervention of coronary bifurcation lesion represents a technical challenge to the interventional cardiologist. It has been associated with lower procedural success, higher complication and restenosis rates. A bifurcation lesion is deŽned as the presence of signiŽcant (greater than 50%) stenosis involving a parent (main) vessel at the ostium of the side-branch with or without sigR...

In stent restenosis after percutaneous coronary intervention

New stent design for use in small coronary arteries during percutaneous coronary intervention

Patients with diabetes mellitus, of female gender, increased age, and/or with peripheral vascular disease often develop coronary stenoses in small caliber vessels. This review describes treatment of these lesions with the paclitaxel-eluting 2.25 mm TAXUS(®) Liberté(®) Atom™ stent. Given the same stent composition, polymer, antirestenotic drug (paclitaxel), and release kinetics as the first-gene...